{"id":"W2233483325","doi":"10.1016/s1470-2045(15)00515-x","title":"Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":424,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; Cancer Research UK; North Carolina GlaxoSmithKline Foundation; Novartis; Celgene; Bayer Corporation; Bristol-Myers Squibb; AstraZeneca; F. Hoffmann-La Roche; Astellas Pharma US; Pfizer; Durham University; Abbott Laboratories","keywords":"Sunitinib; Everolimus; Renal cell carcinoma; Medicine; Oncology; Open label; Internal medicine; Phases of clinical research; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007000471,0.0003727085,0.001289851,0.0000864935,0.0001733077,0.00003348157,0.000506153,0.0001139465,0.0003221618],"category_scores_gemma":[0.0002119824,0.0001812497,0.0001288591,0.0001467161,0.0002019823,0.00012002,0.0001515675,0.0002098932,0.0001454152],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004515148,"about_ca_system_score_gemma":0.0004801546,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007915556,"about_ca_topic_score_gemma":0.00005600007,"domain_scores_codex":[0.9973472,0.0004915844,0.0005315926,0.0005183851,0.0003414321,0.0007697847],"domain_scores_gemma":[0.9958407,0.002417793,0.0004390298,0.0007722495,0.0002576581,0.0002725954],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9768999,0.005723229,0.0002960944,0.00009473922,0.0002828521,0.0001825919,0.000376411,0.000001263377,0.005750544,0.00001529163,0.004935528,0.005441555],"study_design_scores_gemma":[0.9201706,0.0546909,0.0007159248,0.00004325932,0.001600105,0.0000107673,0.0001090793,0.00009499256,0.01122158,0.00002444883,0.0110783,0.0002400402],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9788777,0.00009767083,0.0001782439,0.001228311,0.0005388852,0.009313815,0.000159374,0.00003768562,0.009568274],"genre_scores_gemma":[0.9920565,0.00003876462,0.00386818,0.0005404098,0.0005466934,0.0009794561,0.0001292102,0.00007276473,0.001767943],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0567293,"threshold_uncertainty_score":0.7391149,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0994465300835262,"score_gpt":0.3632002380958994,"score_spread":0.2637537080123732,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}